Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Pharmaceutical Executive: July/August 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
An AI Pulse Checkover 1 year ago
A Promising Option: Exxuaover 1 year ago
Opening the Door: Omvohover 1 year ago
'Marked’ for Stardom?: Truqapover 1 year ago
Branching Off: Wegovyover 1 year ago
A Formidable First: Winrevairover 1 year ago
The Future of Launch Excellence is Generative AIover 1 year ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'over 1 year ago
Big Bets, Bold StepsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
2
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
3
JP Morgan 2026 Preview: Roche’s Refresh
4
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
5